EXEL - Earnings call transcript Q4 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Full Year 2018 Financial Results Conference Call. My name is Andrew and I'll be your operator for today.

As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to your host for today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. proceed. Please

Susan Hubbard

and quarter for financial and call. Andrew, the us results you fourth Exelixis full thank you, joining all for conference Thank year XXXX

development me Chief Haley, Officer, review XXXX. our our for Vice quarter President Chief Mike progress Senner, Joining Medical Peter who Chief and Senior call our Lamb, Gisela ended Commercial; commercial, CEO; our our our P.J. will and research, Officer; fourth corporate, Chris Morrissey, XX, Officer; Financial of today's on Scientific together and President the financial, December are Schwab,

During using tables not website, release, our the call non-GAAP such these today, which principles. we accepted reconciling press will well our to measures on for refer posted for to measures, as an calculated GAAP financial to Please measures results. is today's explanation according refer of as to accounting reasons generally the

today. from you expressed by identify the the company time We we with differ over and which those I from And, course could writing to During to that, developments the involve financial, regarding the matters, which events materially factors certain and of materially. call we or time documents to cause forward-looking includes all Actual results and differ and making SEC, refer assumptions, about events that presentation, heading with the the of This statements important of will the to regulatory, could, uncertainties. will of Factors" commercial, future file Mike. under "Risk discovery, company. clinical, actual course, turn statements performance this in future strategic results be risks, the regarding possible verbally

Mike Morrissey

our a joining quarter and and the overall throughout thanks All had today. full-year commercial, which reflection financial on the success right. us perspective, from and a of a call strong is Thank to XXXX. everyone momentum Exelixis Susan, for fourth clinical, you,

CABOMETYX XXXX move in a today, to executed revenues, new using TKI launch the the last rebuild in cash our momentum strategy the we cabozantinib, from continued from of or to potential work cell with make we carcinoma, wave year We're pipeline. aggressively as the earnings, our to on grow in RCC. as indication, next in renal As initiate QX label-enabling studies you'll and and No. the hear team to X CABOMETYX

was while for quarter, As demand the CABOMETYX the in third this again the we in meaningful case for other decreased in business saw TKIs QX, notably indication. growth RCC the

summary the of Non-GAAP and million, and brief CABOMETYX inhibitor, face been the franchise performance competition earnings drive to the and, with of fourth business Chris, our cash in a commercial projection stronger CABOMETYX, Our continued the highlight supports or finally, best-in-class of the begin checkpoint remains include, future to update QX was foundation full-year for today emerging key on of XXXX income in growth that TKI growth turn XXXX cabozantinib's from QX an our the $XXX share. based cumulative full-year Peter, and I'll based call from for strong net revenue efforts, $XXX for activities. in milestones $X.XX immune and performance Gisela therapies. QX million, QX ICI, earnings, respectively. non-GAAP commercial RCC. for on details data that that by emerging our results discovery has million strong growth and P.J., per diluted revenue, highlights development advanced the quarter of $XXX Cabozantinib and then of providing face Key XXXX from our significant profile financials, first, was high and widely The XXXX prospect for cabozantinib's the never competition. anticipated the in the over quarter

shortly. fourth the $XXX ended Importantly, investments. XXXX and with quarter million Chris cover cash financials will XXXX and in we full-year

of fourth performance CABOMETYX where supported market as continues strong throughout CABOMETYX maintained gain to by RCC the the advanced preferred untreated for depth continued additional update and majority the RCC. share leadership quarter, and continues the TKIs of the for its best-in-class RCC business, its for as patients. TKI indication. CABOSUN the TKI position this The previously Second, to CABOMETYX RCC label and advanced both from the refractory the breadth and in METEOR differentiate approved broad all recent other NCCN data of

CABOMETYX we in regulatory the and development with launch immediate to and our program, advance approval second-line Third, cabozantinib continued recent HCC. of

to RCC, cabozantinib pursuing begun VEGFR rebuild external MET in the our inhibitor, pivotal next-generation them and including throughout this portfolio agent with of recent collaborations, first-line aggressively bear are to late-stage cabozantinib finally, additional and with XXXX. area stage efforts and our highlight DTC, seek next start combination of COSMIC-XXX wave set CheckMate advancement status. reinitiated internal Fourth, and of we a of trials, development Through late-stage efficiently the internal to trials the discovery COSMIC-XXX setting. first-line the Three move clinical efforts HCC, for and combination candidates in the progress We single second-line trials. into with with fruit combination cabo/nivo in in XLXXX, a clinical XER, the have cabo/atezo IND to

components to reinvest full-year progress seek business to growth. expenses into reflects manage sustainable free across long-term revenues, fourth the build and cash of carefully, our and throughout the our business. team's Our outstanding grow quarter XXXX all performance We

to our patients single enter XXth year every goals focused on we since deliver Exelixis' and founding, for day our we As stay and shareholders. both are determined

the Chris, provide call with XXXX that, more will turn I'll details who quarter fourth over on our financials. So, full-year to and

Chris Senner

you with pleased full results fourth of and very I'm for Mike. financial Thanks XXXX. year share the quarter our strong to

eighth our X%. the XXXX is Total On of of entering to revenues to the XXXX the during year third million whom quarter increase in with quarter-over-quarter our a at included price $XXX.X year at full from increase first as will to an of we CABOMETYX the start as be increase of commercial fourth dispensed operational from revenues increased our consecutive in fourth million, also donut the for and fourth The our We result of price by $X the of partners, Overall, increase $XX.X respectively, XXXX. for fourth quarter million reported and of frequently that company wholesaler quarter. sequential quarter was which X.X utilize gross was will This to in for increase quarter which CABOMETYX $XXX of full-year our This demands, million, gross of milestones full be revenues $XXX.X net approximately the the reflects quarter assistance total this in increase was XXXX, XX.X%, was to of line quarter and revenues of this calendar approximately well product net sales year cabozantinib net $X.X for when increase would recognition inventory the of product year-ending percentage revenues XXXX, XX%. patient of profitability. CABOMETYX to year Total million took our the say impact XXXX, the net a be full and and the many year, in Offsetting million included approximate wholesaler in hole XX.X%. the Medicare of consecutive program Takeda. approximately for approximately commercial the related and third primarily Ipsen compared from a XXXX. deductions guidance $X.X in deductions million increased in million inventory of of and for approximately are the The point in sales came year. an XX.X%. the basis, company's million, which that million the collaboration $XX.X end positive proud $XXX.X was or quarter our $XXX.X second that an the which gross is the more patients, copay patients to gross of

inventory. the Additionally, over quarters, unit two XXX increase approximate seen an we've wholesaler last in

increased of the this demand support but inventory related in was to increase increase Some hand. wholesaler on the weeks the increase of to was inventory an majority patient

appears what As previously. exiting was results, companies some several biopharma wholesalers seen by their carried when other has QX discussing inventory reported than XXXX been more it that

commercial always revenues fourth the revenues of is XXXX. and Collaboration supply and ended revenues quarter XX, include of for that collaboration. development, inventory Ipsen Takeda. of partners, may As from CABOMETYX $XX.X their recognition first XXXX milestones include and from our during from earned of the were collaboration recognized the license, wholesalers revenues the quarter royalties case, also levels of the $X.X for revenues company's also $XX.X million December from quarter additional collaboration include $XX.X Total million XXXX. million of is product there potential Ipsen, million reduce research $X.X of million the and in the Collaboration of royalty that profit-sharing Genentech,

our discussing fourth on fully quarter, of for the taxes cash be diluted SG&A in tax full the per of GAAP after in for services, compensation. GAAP primarily starting for and $XXX per compared per was for assets spend reported year these net details determined and restricted substantially outside and benefit would provide million XXXX. million valuation than million, valuation income degree, The and a primarily the fully $X.XX $XXX,XXX.XX The primarily year. for million, all investments or a Our benefit expenses was XXXX fourth of ended increase income share expenses, was and of was or of total a in that not respectively. XX, total to stock-based on to and will million a $X.X for share provision fourth the record fourth and related short- non-GAAP guidance was XXXX. reported of the million, tax by on tax The quarter Selling, Income during the $XXX the an increase in recorded deferred the costs basis, to income of year non-cash to for XXXX. to The $X.XX realized. will clinical and compared for fully Non-GAAP company's expenses XXXX $X.XX we million $X.XX allowance I fourth rate, long-term income benefit trial company million XXXX. general, share release third and tax release increases diluted of company it quarter, assets. the estimated our for and and the in expenses fully is XXXX the and made tax result and administrative million, $XXX.X to and, $XXX the current the of quarter of million in costs. XXXX valuation $XXX.X or equivalents, income the a for XXXX, The net increase year Due $X company release the the quarter on Cash against the Within for personnel deferred XXXX, in basis was approximately million cash excludes per that to year of basis, XXXX, the $XXX.X but approximately lesser on diluted $XXX decision of when share likely XX, income or in using which allowance full personnel, quarter $XXX.X $XXX.X quarter net was million, $XXX.X long-term R&D of basis, includes of an the the expenses diluted December of tax $XXX.X tax cost million. related income and allowance December totaled at XX, period the full at increases investments, were fourth XXXX, XXXX. quarter largest effective December more increased the the cost income consulting and

of opted expense expenses Selling, related of financial to $XX turning expected begin and of and And quarter in line administrative growth. our we and general, Guidance $XXX $XXX growth and be to invest approximately and of expense as to effective this be detailed more expected to expected between than to net additional to related includes million the measures visibility that revenues. million XX% provide XXXX that, which product Now, be business Research stock-based million, provide color to is XXXX, million between XXXX, to order is X% financial long-term its I'll previous cost in goods million. nature company company $XXX exclude over and million. is development the to results. sold P.J. and of $XXX compensation guidance providing following call the drive to between the in expense approximately financial per $XX of for our between stock-based plans XX%. to starting tax in the is stock-based non-cash compensation X% the item, continue first reporting The drivers financial is for guidance, We've is to more With expense non-GAAP our to compensation expense years. in the from rate turn

P.J. Haley

of saw CABOMETYX grew in clinical TKI by and approximately pleased of QX CABOMETYX QX more prescriber the we Thank very demand strength over today NCCN utilization of choice broad CABO XX% goal The QX, market base achieved in lines in you, We across continued in X% therapy, Chris. in of demand fundamentals, and growth as of QX groups. the and QX. CABOMETYX strong positioning favorably, X% market. share community in you our expand to discuss gains academic RCC, an the as risk fourth relative continued I'm CABOMETYX the detail establishing at fourth the with and in grew guidelines increase relative in settings, Also, rate to the quarter. to the business to quarter. of the performance of updated demonstrated by TKI

that and to and This last QX. Based We and has this kinase relative RCC X% oral in on share continued order data, of tyrosine the significant for IQVIA pazopanib, available in competitive continued TKI, get or better CABOMETYX despite dynamics, analyzed the the XXXX inhibitor, year the competition. quarter represents are a the QX pleased sunitinib, National CABOMETYX. Prescription publicly grow sense a of comprised to market, evolving progress to QX in data to Audit In to we from a increasing prescription share, ago. increased for market axitinib, increase XX% CABOMETYX point XX% grow

In of RCC. which and is also CABOMETYX aware trend current in prescribed X TKI continues that by for fact, it No. NCCN RCC. this using newly reinforced these show the promotionally to data are This guidelines physicians became the we fact, are ensure

a NCCN population that only cancer. regimen guidelines and recall the makes for for TKI up preferred is XX% a approximately first-line now You in the kidney is September, published may the intermediate updated first-line market. risk poor of CABO that patients,

patients recommendation by continue sequencing and, totality an label robust second-line receive of Importantly, preferred to also only to lends combination will checkpoint who of have either RCC the thus METEOR strong ICI the further ultimately, CABO an checkpoint be to the relative for making the patients choice have the inhibitor, broad The credence quarters. will trend differentiation expect of opportunity regimen added strengthens from the market therapy, and sequence. ICI, largely combination. who by for have positioning is in continue primary the increased to or guidelines well-positioned progressed the QX CABOMETYX to by and driven the Most options. CABOMETYX to CABOSUN other data for This patients the number is TKIs. in therapeutic subsequent on and that RCC immune combination for TKI coming followed or The inhibitor patients. CABO already received immune CABO therapy we nivo/ipi in be of these CABOMETYX in treatment of followed

patients the from and opinion surveyed whether combination, option Impact, the since the as CABOMETYX business or to TKI. into therapeutic majority nivo/ipi their choose indicates would who IQVIA share both strong as ICI on first-line of this it regardless second-line data Furthermore, after patient a CABOMETYX The XX% their the agent. in PD-X market progressed key of Brand QX. in XXXX. heading has CABOMETYX nivo/ipi in of receive is research April, new momentum first-line Our of combination the approval RCC leaders According increased approximately second-line market have a

share I data fact, mentioned just progressed approximately market that QX CABOMETYX who above. of with from in nivo/ipi, that have our IQVIA suggests market patients research consistent Impact captured on In Brand XX%

RCC grow Given of flow the dynamics the continue to we and strength XXXX. CABOMETYX expect data, the demand patient to in

XX,XXX the to become Liver In with year. there a over new therapeutic in in on the research treatment. deaths key single accounting patients addition will HCC more drug-treated CABO even to indication patients of to globally attributed we Group Exelixis tumor a growth are indication years, not opinion drug-treated increasing only have as that market XX% CABO/ICI third expected the XXX,XXX patients franchise. to RCC, leaders the receive their excited and in The representing diagnosed CABOMETYX need, number the of are systemic both cancer due each medical combination to incidence liver are the of annual continued an increase treatment received at potentially newly Resources cabozantinib for in intends to as more the and increase difference momentum first-line coming in patients In is and drive increase more in fourth of unmet by to type HCC, will The of of grow U.S., potential basis. is therapeutic XXXX for become significant and the firm the the significantly with the play predicts advancement more an in a approaches. U.S. even key therapies as options market approximately occur systemic therapies increasing over The for rates second-line XX,XXX are in XX%. role is deaths HCC options and multiple and receive these cancer of drug patients of will available. but lines introduced patients, greater agent so therapy also available, an Decision indicate disease

Upon launch many press pleased after non-personal executed strong are of and we approval our January We on quickly minutes the within initial mobilized tactics. our team. and XXth, personal execution with the salesforce release promotional

medical commercial a heels has presence from at KOLs HCC. this specialists and January label the and with launch, comments opportunity affairs the CELESTIAL held discussions approval limit new top on used have we've ASCO-GI XX-XX immediately will The oncologists of with the majority time and to HCC CELESTIAL the on week. the of large my received. great meeting discuss feedback that the in GI prescribers from qualitative as and the label on data in provided Francisco an positive. early it very the totality and HCC is top opportunity I of to We it been at the to this feedback had the data early As was San in

Importantly, number well. the HCC only the prescribers increased and access for RCC account salesforce HCC facilitated as approval productive and not has discussions interactions has but meaningful our of with discussions increased

covered and calling In fact, footprint HCC-specific the immediately began market approximately and we of potential approval. on remaining combined RCC prescribers HCC sales RCC our preapproval the XX% following

Our interest there increased This be HCC market research confirmatory is research. proportion early previous had community had of experience that and an indicated for the the would if large represents segment prescribing in CABOMETYX in using the of CABO oncologists in physician a feedback setting RCC.

data the this We potential are perception positive QX help results added HCC, prescribed options in and treat forward trifecta in development other on to indications approval more they as of now of program we many future in is patients No. CABOMETYX X momentum now strong customers but TKI in and our the RCC cabozantinib gives This augment CABOMETYX. RCC, the building patients overall as more with and brand expands. from response the to the RCC to rate strive pleased CABOMETYX terms to believe of and and look that cancers. continues difficult addition to data. with HCC of could the has the label of HCC the patients benefit OS, PFS, improvement another with

the day continue compete benefit And, motivated I and that, to Our the franchise. call Peter. over we to patient will team of as build bring eligible the to with is to every turn to CABOMETYX every focused

Peter Lamb

for update and our adults delighted Sankyo partner I'll Sankyo. development potent right. from partnership XXXX. Daiichi commercial we a registrational digit patients were Exelixis name on our start significant toward have blocker positive Japan there hypertension in milestone Japanese announce with also January effective milestones There received receptor sale approximately are are commercial from the essential on mineralocorticoid X collaboration in Daiichi that provide need royalties. directed hypertension. Daiichi a agents blood for We for first with on our update trial the a and regulatory a in based was ongoing research million The P.J. treatment identified the on new an and pipeline. who of is with in pressure. efforts selective with Sankyo MINNEBRO, essential $XX that Japan, treatment to commercial Phase receive XX I'll the eligible Thanks, payment our high All upon esaxerenone, patients approval of an expanding MINNEBRO in will with of during given for data is hypertension. additional and approval MINNEBRO million from low-double programs

have I'll also active multiple reestablishment biology our Alameda with XX quick advancing in is development in In potential discovery are guiding earlier-stage additional if are to in the locally addition, finish fourth programs melanoma the for cobimetinib this previously which development the filings rebuilding cobimetinib Phase combining quarter in are our in are conducted new supportive. labs second of cobimetinib capacity. and small into with aimed process now Phase of identifying melanoma, business Roche and at full the mutant-positive, nephropathy, Phase now pipeline a the diabetic patients. XXXX, in builds efforts, studying Switching our in These Roche melanoma. wild-type approaching Daiichi data X trials chemistry and different which in BRAF and atezolizumab molecule includes encompass BRAF XXXX internal regulatory trials untreated discovery ongoing patient are the trial progress with on patients that pipeline. of with IMspireXXX, or groups oncology IMspireXXX, is clinical fully the previously untreated update tumor in fourth atezolizumab which assets of a currently cobimetinib this and trials, development metastatic our combination active our is enrolled Japanese Both initiated TRILOGY, was and and could and the types. quarter advanced vemurafanib in Genentech, internal studies which trial, later year initiated We in population. trial collaboration Roche program X Xb an sponsoring Sankyo feed that off previously capabilities include now both two metastatic

report announced some first now plan is details that clinical today, subject regarding IND. compound an initial discovery the Gisela for development VEGFR XLXXX a efforts, inhibitor the next-generation am XLXXX, restarted in to I from active emerge of the to provide MET pleased designated our moment. a will As

the two On advance with good StemSynergy advance our antibodies. BD with front, compounds a signaling, making other bispecific inhibit first class CKXα we're collaborations, pathway that and one the progress novel activator to of to novel with Invenra

Finally, to With we had in our materialize. are forward. J.P. the process the on reviewing multiple in a the Morgan Gisela. look you this progress of conference at best ones that, things strategy the I'll to evaluating opportunities pass We front on our and currently busy forward call week with January, going updating as that further fit

Gisela Schwab

second-line a Thank an by brief to as update start in Peter. program regulatory with update pleased the marked the was progress on important you, I provide milestones. fourth I'm quarter. on of cabozantinib development will quarter the HCC, the

First, more HCC, who in September we CABOMETYX for November XXXX. and new with been the approvals progress submission approved as in indication approval second-line bring a with very positive this for XXXX, the of United beyond pleased January are in allows And adults of for therapy new date one FDA the treated XXXX, recommendation indication, late-breaking European to in approved followed HCC have us cabozantinib news, previously by to sorafenib. advanced XX, cancer expand CHMP HCC patients indications cabozantinib in The These important for the that treatment regulatory into therapies. RCC our the States. of need in this a Commission on

management on including fully evaluations the inhibitors plan through With checkpoint these are development achieved, immune combinations single agent broader we and cabozantinib, with milestones Genentech-Roche. BMS and and important with for collaborations lifecycle focused our

studies have Phase X pivotal in Two differentiated made in separate we Phase evaluations. Quarter PFS planned calls, already of in a a interim This patients planned. analysis XXXX globally. for survival. cabozantinib as involved. of trials trials initiation multiple the advanced while start XXXX and conducted of of been activity treated in that to to the cabozantinib reported therapy. and COSMIC-XXX, prior time involved XXX and on initiation has co-primary for received analysis and such have designed with on have are analyzed endpoints analysis. XXXX with have two today. have XXX an total be these Phase all October, among durable placebo-controlled response objective various X in XXX first follow-up, and will X trial The the tumor response study in prior progress previously to among little be mentioned appropriate of will progression-free been response rate work trials XX% at the cabozantinib objective PFS more trial of thyroid X we with patients encouraging X our The enroll patients the cancer treatment X will objective announced in the rate based planning pleased cancer on and patients with provide event-driven rates advanced VEGFR-targeting rate response we As color be a I'm of thyroid trial, In will who This a differentiated radioiodine-refractory types of Phase There's to XX%

patients exploratory agent cabozantinib involve executed to our inhibitors, are compares checkpoint X sites. combining we a with HCC. the includes activity are cabozantinib with standard overall also progress very be with study the atezolizumab to This with globally, initiated study combination study survival. Phase XXX contribution combination will of of XXX address combination with pleased and Regarding involving endpoints cabozantinib clinical December, of Co-primary arm the an treatment of In It the first-line will sorafenib. than in PFS study of Genentech-Roche. this and and for cabozantinib we of more care: collaboration single atezolizumab. The the

cabozantinib that combination various atezolizumab of study with We ongoing Phase under planned settings. different evaluating and was pleased now tumor our Xb this dose initial expansion The trial, the COSMIC-XXX, combination study in evaluated in are cord is an way. in dose-ranging

combination expression. the Initial and of previously for with cabozantinib, response, complete seen active RCC with identified including and durable in activity well including were part a PD-LX Grade Grade Neeraj combination an of XX tumor adverse have malignancies, was was X trial. and in showed observed in tolerability XX, atezolizumab conference variety non-small the clinical events combination cohorts, by This cancer, of types, at Munich cell combination dose, XX%, no histologies good no encouraging and ESMO combination cancers, recent generally The the seven expansion this of lung of regardless Agerwal. for and toxicities Xb actively dose-limiting We XXmg presented atezolizumab, confirmed X the were X tolerated data does enrolling achieving the into partial Dr. Anti-tumor Phase gynecologic dose-ranging malignancies. activity, or with events as one patients with of trial There GI observed. response. X the few cabozantinib across untreated is different patients a such now GU or

with and combination clinical study making Our treatment-naïve patients in X The cabozantinib nivolumab globally. ipilimumab, collaboration enrolling versus with in is XER patients great nivolumab CheckMate nivolumab combining evaluating both with alone Phase RCC sunitinib or BMS, cabozantinib also progress. is

is collaboration co-funded recent XXXX, results half second by with We as are from the expecting together Ipsen BMS's ourselves the This our on partners, who of this and X study. call. was and Takeda, trial BMS, Quarter is study shared in conducting

safety combination as and anticipated in the for provide agent we And, filed studies ready internal advancing ipilimumab XXXX, our an established the Additionally, as our patients are Phase bladder Further expansion, the Peter will now first-line on plan efforts pipeline. from advanced nivolumab, malignancies of are emerged as tolerability of setting next-generation with start and cancer new dose the trial ongoing genitourinary more cell initiate disease-specific, triplet cancer working ipilimumab and including trials. evaluated which late-stage development. separate nivolumab and MET, dose-finding IND we we that approaches, we targeting Data activities this non-small kinase And compound is details in to trial these in late-stage a for discovery we for this single be Quarter and to Phase development triplet in stage RCC also get lung investigating inhibitor active. preliminary for Late combination as and combination. quickly and tyrosine a Xb mentioned, well combination IND are through cabozantinib, inhibitor lastly, X forward recommended has VEGFR advancing checkpoint dependent, the as on of and continues combination and in planned. indications X actively expanding versus

taking in in and later San am with week, program conference place the I Francisco. Also, quarter with updating forward in and to summary, development annual made in So, milestones the important during this this very is pleased reached the you regulatory our ASCO-GU the look future. progress

and turn We the back I'll where opportunity cabozantinib-related leaders to that, are to the opinion partners. And, Mike. be looking and XX will the forward connect call person abstracts presented, with conference, key in with to to

Mike Morrissey

continues All fourth in see XXXX. strong of as right. a to quarter move had Gisela. solid growth our business Exelixis and Thanks, all aspects into we

new label-enabling external commercial, product performance a like and would XXXX for keep strong future in in notable I two are focus. issues emphasize R&D through opportunities to portfolio that trials adding regulatory, our and provides and product Our important cabozantinib to key efforts. financial with internal platform rebuilding

to will the build TKI continue for status on RCC. the its strength Exelixis of First, and CABOMETYX of choice as

to in some to therapy. from benefit journey so we third-line point RCC every Our target continue their target that CABOMETYX broad day every first- commercial RCC RCC opportunity patients and can single the from patient eligible efforts potentially at

as seen combinations. trends refractory the patients. to future front-line we've not for therapies appears and, KOL the they and current surprised of Based majority be research, CABOMETYX become ICI choice that refractory by TKI these real-world most patients importantly, on feedback, in recently, of success market RCC vast the We to ICI combination and expect ICI-based are subsequent will strategies that of the need

come. previously, RCC care the position refractory opportunity said to first-line an see provide with eventuality we as care, opportunity an second-line ICI fortify as ICI CABOMETYX go-to its combinations we've standard for for growth standard of As which dynamic, the evolving for years to multiple of patients, compelling could a of as

activity combined cabozantinib's to to potential indications has a agent tolerability, broad tumor safety and next-generation seek encouraging this approach. activity, on molecules and single types as with and demonstrated when of we ICIs. in the advance Second, expand clinical shows multiple build Cabozantinib

dedication pursue its data-driven, to in thank pursue time, the potential vasculature, combinations. next for appropriately. expand that valued the we of assets closing, pharmacology Our immune I chapter At entire impact we'll the a compelling same story. financial and of a next-generation tumor approach and depth and on EXEL the cells, position knowledge deep, In work the commitment team Exelixis rational and compelling such indications and want us fundamental use as rationale aggressively as their growing iterative, our the write tumor provides and with our intend manner to cash microenvironment this We range to partner to CABO's acquire highly to compounds, to are of or XLXXX.

perspective. commercial, XXth next more every EXEL year, develop, stronger discover, and of never better from patients generation effective continues be clinical, been of commercialize enter cancer day committed medicines we we financial count us to our Exelixis to as our are making and we in by inspired and The the As and for of the and opportunities energized has need ahead team a therapies.

with So, our the continued questions. now to we look and to Exelixis you happy and thank progress updating your open interest for you we're and that, for call forward we on support in

Operator

of Andy [Operator first Please from Instructions] proceed. Blair. Hsieh with question the comes And your line William

Andy Hsieh

I feel ATC, have patients, recently. do radiologists for First oncologist dynamics their question for patients see options patient as you of to hepatologist In colleagues? interventional we comfortable evolution P.J. if wondering or an their in the just mean sending is What management field more more experienced

P.J. Haley

and market we as be us indicated, I kind a What think HCC. this seeing the to approved launch time. was many are isn't in excited and of previously, options dynamic, by therapies. given indicated to have approved the more are there And for really mentioned, to radiologists, a is we've the option quickly I in as it's hearing with more that with from and for others, the be of which kind now that you regards setting, the many long to the flow patient you as sort is built starting early recently of oncology Certainly, interventional flow days by surprising into is will which only KOLs will, that if beyond sorafenib, us

our and increase drug just the XXXX XX% dynamics the even this patients the the And to second-line, increase. by in higher rise. rates I referred it's patient number, in I by a expected in and the treatment fact first-line, that's the script to are patient Decision an being flow quantifies and, driven that by dynamic it's XX% over Resources to think Group time expected data drug-treated that

and gives indication well have to where we the as the these that about great HCC RCC. the with it us pleased very the So, talk with data happy opportunity community oncologists, discussions multi-tumor can as in

Andy Hsieh

P.J. Thanks,

to So, do in second has RCC setting. the question

potential is combination. which obviously, is TKIs. XL, all could data I the Keynote-XXX, my one guess, targets just of at was that IO/TKI guess, I the some out mechanism unique among remind are for least, the in if, us what wondering I there. unique, published Peter, escape been have view, approved the strong of or, immunological you chemical tumor implications So, which, it from reinforces And aspects cabo

Peter Lamb

RCC, comfortable for kind question in agent to be renal cell targets one development is version question we've the for I'd - the those cabozantinib happy to now that came comparing showed some a - been clinical head-to-head role the position then, we it's broader our always front-line question TKI in question. tumor of MET good If think the recently, additional the and single was, And that while. go were would does one. broad with for is Thanks So, we cabozantinib going to not And that is as I superior with sunitinib, data, carcinoma, cell. of and renal modern in a sense, inhibitor original of I are think leading XL CABOSUN that its you people to in the and as that idea combination RCC they obviously led back VEGFR a approval the of a in the in usually mentioned that add? XL more but get in kind VEGFR very microenvironment. asking inhibit what which answer a of cabozantinib inhibition targets, And really minute, answer of that the vascular, benefit. in of inhibits of and in one, to role reasonably was a another as that I'll around cabozantinib would a role the result it's the tumor immune MET biology the with other

axitinib the would data with a baseline in VEGFR And MET might the XL a immune combination the expect of is, VEGFR and pembro selective question be beyond and what you a be. kind of data or there's compelling the and benchmark, if inhibitor, impactful. the like. we indicated, might obviously might And pretty targets Axitinib very suggests lays context cabozantinib you scientific a I inhibitor as checkpoint of is with an what that role that with also inhibition. think XXX those rationale now, So,

to be XL, So, closely an those immunosuppressive role expressed expressed, state. be are you in to of sibling, mentioned it's is really there and it, And kind put known to with since in known related their its tumor-associated macrophages macrophages.

is by that subset presenting and in that completely interesting MET cells known more also, escape cells, preclinical to a activity. kinases, to dendritic system, very to be flip natural over mobilization suppressive specifically actually, also the microenvironment. And, of of upon for thought last macrophages kind MET specifically immune those immune of is to suppress with respect into checkpoint activity. innate killer MET from at on which we With those cells their a So, dependent models, year, a published blockage looking to immune premier tumor inhibiting state. respect you expect MET, see was there's a the Activation might permissive in the are of paper antigen role

be as immune and the couple with And cabozantinib So, cabo's impactful. over at we XL on the that's adding going years in respect system, to the look we last in the of you MET as inhibition, on. impact certainly both that emerged is three going tumor-associated things profile, basically see to believe data

the visible and where So, tumor immune expression, direct see a a more we you effect the tumor Class pre-clinically which to system. makes as cells the clinic, increased Both immune see tumor in pre-clinically, we X operate as numbers on MAC in we finally, both t-cells, numbers cells, models. MDSCs. the such see t-regs periphery And, the immunosuppressive itself and inhibition both and/or of activated and cytotoxic and of on in the pre-clinical activity of cells,

both that kind a and system is it's the generally innate impacting immune pointing adaptive creating toward like and profile the So, environment. of immune-permissive more

Andy Hsieh

Thanks really answer. for detailed that

So, me for last Chris. one for

a for quarter, talked I weeks. in any think last the update quarter? terms the this quantity there half of and inventory on-hand, sort two you Is of about

Chris Senner

I mean, so I'd a answer in couple that here. ways of

X% guess And focus a mentioned, in X% growth demand ICI demand for as by roll P.J. really in off patients saw Right? starting the us see out, So, That was a and we growth CABOMETYX. QX. QX. P.J. preceded As demand the we on into is I growth. pointed are to

So, we story. continue a demand this think as of

half again, weeks said, being to rise saw this is so weeks. we inventory from wholesale an story. a two the see some But, still and that do around we hand story levels in and a inventory and on Now, very weeks fluctuation did not demand think around we X.X much

it there. for lays pretty well in Slide can you slide refer because XX out deck to the You that

Operator

comes next proceed. question of with Securities. Please Schmidt your And Michael Guggenheim the line from

Michael Schmidt

be to see are the on Do molecule especially of interesting think bit sort might similar paths, to and that might active CABOMETYX XLXXX. maybe development a you Could mechanism? based different management type that or it's here, there how of compared opportunity being maybe comment more see that lifecycle IND potential as next Great indications you or sort the little if you about similar? other be a how

Peter Lamb

this that Yes, take I'll is Peter. one.

our just I in outlined. developed of as but cancer, well of as pre-clinically. there's the the cabozantinib, we've the over treatment think of of the years various to of point, last clinically of And at this I enormous advances been and types as relevance obviously, understanding several understanding cabozantinib So, information amount an

of of something think kind there's cabozantinib we So, like. you'd the about core of combination, special if kind the the VEGFR profile,

obviously a at So, It's that The TKI. It X It's earlier is inhibitor. novel aimed profile. trial a Gisela clinical potential retains VEGFR for differentiated getting the that course. we people. and further has translates XLXXX described develop the based a whether pre-clinical like - compound. data Phase where of to a profile that, obviously, guided - actually that, into the what to data, how see we'll And see us we about on be and

Michael Schmidt

potential On a you guidance. R&D share X your year. terms if have cabo then starts additional Phase throughout on for XXXX, what I'm question could trial curious And do included you of guidance just in the there

Chris Senner

Michael, it's Chris.

XXXX So, our the And expense a there's is and XXX and of driver I'd biggest the question. thanks increase for XXX. really versus XXXX very the say in ongoing just XXX enrollment is XXXX to or we've studies about started already majority related the yet. But for XXXX. amount have small around new that talked studies budgeted haven't the but that in either we

Michael Schmidt

extension then of And in additional of how should here. COSMIC-XXX, terms think from about cohorts disclosure some the data we

enrolled are believe. now, Some time I for of fully some those

Gisela Schwab

actively enrolling Gisela. indications are is very Thank question. we generating that COSMIC-XXX on. about certainly, the for are excited XX different is the expansion cohorts. we across you This data And,

to are going present premature that data. or say to publish Just we not

will and are looking and at to We be at that presented the is conferences publications. that accumulate time mature appropriate data sufficient

So, that. we on update will certainly you

we and tolerability was the signs were that the I and referred in presentation, DOS the conference, such experience call. escalation no We're in the clinical dose-limiting pleased at the the and on one with profile RCC. toxicities to of There activity good back of presented referring ESMO to Just earlier very data combination. saw

Operator

question Please next of Markets. proceed. MacKay with line from Capital RBC comes And Kennan your the

Justin Burns

board. forward. cabo the This sort A forward on drove Wondering of on that out if from any potentially quick the And across ones us on going that how you on Kennen. the questions. taking increased build for couple Thank our close expect moving in XXXX that? to impact what saw you're then you thanks potentially XXXX, to of is inventory feedback for growth quarter Justin into Congratulations you. getting and sales

Chris Senner

This is Chris.

see. future So, industry, of quarter several that also in about the talking looking inventory. the do that biopharma wholesaler the generally, companies demand fourth we think is big it, over would But saw, wholesalers we that increase portion at their

transparency in of your in have SPXX government. some including to place, measures the that put circumstances, been report, where, that in certain to price price could advance, the increase in California And you related to be have

So, nothing may think some that specific that we but of we the driven can things it. to those point have are

Operator

question from Boris Please next the Peaker of line with And proceed. Cowen. comes your

Boris Peaker

now like little the HCC. opportunity. - there's probe quarter. TKI congratulations in marketplace? I'd by comment liver Can I on overall growth the inhibitors to excellent an growth mentioned add just versus this checkpoint my cancer And What bit to in of on just driven want you right further a the fraction is you

P.J. Haley

P.J. I'll This that take is question.

kind early the approval. referred to, it's of in for of I us sort days As

What a So, I speculate new front approvals say I is we're well-positioned. the I wouldn't certainly with dynamic on IO certainly, to as market, that really both want forward. would as well TKI moving think on,

We of point And it have the this use terms is early a anecdotal RCC to our significant with CABOMETYX HCC, used XX% if they've customer prescribers, likely value a feedback, number, market RCC, concentrated of of which we universe, covered already and salesforce. at in HCC. in they're we know that through in which research more

it's launch but think want beyond in I recognize and are early that wouldn't that. to really the signs all So, speculate encouraging those

Boris Peaker

an Yervoy just front-line take Yervoy. in for you Do way and on your of playing the combo, similar data, dynamic more plus follow-up we which data question, saw I kind use is obviously Opdivo Opdivo setting? IO/TKI front-line maybe do for you dynamic? the the setting results to just out And RCC maybe see mean, or general and space. a in saw How this TKI that we Keynote-XXX giving see

Mike Morrissey

be first-line there. or different we've and potentially IO/TKI masse. ago, the some combinations minutes en color I'll the and setting IO being viewed happy of I to moving as either successful Mike. into I think It's few provide mentioned enabling a kind very always as

themselves. right ASCO-GU. obviously, certainly us state us. and It of So, think, seeing the think data upon makes opportunity Lots that with that's we're a data data there's And CABOMETYX certainly are we XER mentioned and now, it data moving of for game data prepared pretty cabo, at at agents, I arguably a up excited talked show the separately Brand our of need as this two what dynamic cabo/nivo/ipi, the see bulk for weekend his as of of certainly, standard two steady about prepared as to of the XXX take nivo I having the more second-line. in combinations in first-line different it's the And, but best-known playing the Rx. pieces. based survival Impact and combined. overall But dependent RCC the, all that look remarks, emerge if But to - by well. some wouldn't remarks, this is potentially, we terms triplet, go-to We're also in by in of coming then as compelling it being sense at some opportunity P.J. care setting. fine numerous The surprise the field. that provides, and about that only from And

indication this for committed our with in going very forward. and times us ourselves certainly can we're as continue to to partners as the work post move exciting work So, additional to and we do to goal continuing high

Operator

Ted Tenthoff next Your with line of comes from question Piper the Jaffray.

open. now is line Your

Ted Tenthoff

two for So, me. questions

overall you that the said registrational? that were on first be Would provide XXX COSMIC-XXX, think Firstly, I patients. on to update an you going potentially response the

Gisela Schwab

response be, of endpoint, dependent. a patients XXX such with enrolled heard So, regulatory positive and steps feel first that co-primary you co-primary that objective And study in any foresees response could obviously, follow-up. assessing response rate sufficient we the data the endpoints. and support potentially are PSF durability And rate me the would that say objective action. But as

Ted Tenthoff

the the a And coming of for Cosmic-XXX, we other and then to of congrats could with questions in from taking other respect some those cohorts? quarter. updates Thanks on great expect when from some data

Gisela Schwab

will data As I and have as to present said data earlier, so and sufficient we do soon cohorts follow-up. as expansion we those stable definitely want from we mature with the

so when and when available certainly are will data loop such And keep will the presented. and communicate they we be in everyone

Operator

the line with from comes of SunTrust. next Lawson Your Peter question

is line open. now Your

Peter Lawson

and what we thinking the are be Thanks we could takes puts up color for questions. it the of be about? XXX? timing should thinking XER? any and XER about stack should versus Anything the taking around just And Mike, how

Mike Morrissey

together being the doing. too said, I not just look, improve pivotal we're to obviously attractive much speculate Probably and and Boris, that two an both, is the with cabo with want as doing in triplet So, that well, on agents doing answer which and something combining XER overall my to ongoing It's sensitive with to is survival this bad with trial. which idea in nivo looking That very indication, we're we be cabo/nivo/ipi. to think I don't form. of should forward

these microenvironment. So, really again, heard from Peter is working how we the have as but as the of agents, momentum space, tumor activity lots fundamental lot of clinical understand in not immune and clinical the a have this of this mentioned we as interacting interest a only well, you feel we cabo in understanding today, We Gisela in space. like pharmacology of and

done got going forward to we data data for the and and we've hand. and of have get in us just So, get things a that then it lot with move now

Peter Lawson

of physicians combinations kind use What's with of And TKIs and feedback you versus sequencing from what individual IOs? are preference? the around getting the

Mike Morrissey

take want to you P.J., that?

P.J. Haley

Yes.

or we've that's that, as TKI, receive players mentioned, that big seen. the the cabo at would it's patients nivo/ipi in talked of will so all of think of always nivo/ipi sequencing do the indication extent, research whether In QX, I And on approximately single remarks. looking maintain we role. data as out importantly, TKI a seen, to, still large in the on of And in my thought of about be to think borne cabo. therapy little regardless is some the by there. landscape, the we've in that went bit be I will plays far in a certainly terms XX% it But, PD-X second-line market progressing the agent certainly, really position the combinations, first-line. What to been Mike kind the prepared choice the we've We we've is an alluded first-line. done,

METEOR a our and the aligns the really It our So, of we're positioning depth really data studies. guidelines and messaging. CABOSUN the pleased with that breadth NCCN key with and the label in in and our both part that's and of

So, increase in will patients think I second-line patient of dynamics flow the we're capture continue nivo/ipi, the coming combination and patients think those those those to we well-positioned off patients. to

Operator

line And your Silvan of Please with from Oppenheimer. comes Turkcan next proceed. question the

Silvan Turkcan

you looking maybe the you that if you I you just you tell an are please? about of you another give bit me Are BD for with combines question. Could and Could looking cash well details, kind quarter TKI? just my for the on a you mean, taking clinic. little you thank and can, some mean, little I asset put color into TKI? million us your there, a Congrats for in one have about $XXX strategy?

Mike Morrissey

It's few Mike. happy to I'm say words a there.

to late opportunities So, commercial. to a late clinical even very of valued looking approach for from clinical look, we broad appropriately to have here, assets span early range that the pre-clinical

we assets. good appetite certainly, I deeply last much vision while kinds wide think of range early have more of number broadly we of and pretty on could did a at and those where with So, much any a looking, pretty big year, a stage of We deals a more assets. go

allow possible. we're commercial drugs the as Certainly, products, us biologics strategy to and that would that right them them as setting as our that or So, the the as looking some to well underscores develop pursue data for would efficiently agnostic kinds the good and of them either move we interest have allow us into the with quickly in kinds But right that. for looking to compounds. of think, modality. right I in We're deal have Invenra,

deals, think that about next wave would of as traction the I on great in broad, more and much again, think talking would I detail. So, get we'll deep, be we,

Silvan Turkcan

And the there as maybe bit also respect RCC? HCC? ramp KOLs of prescribers, lot is size in peak and you get HCC up your to since a of to some opportunity to sales estimates, us margin in tell could a about the terms maybe overlap And a and little of way internal speed in there's expansion with

Mike Morrissey

RCC as previously, ago a between the enhancements, were and be fact - a footprint, able to able there's has minutes us as to HCC about to Well, simultaneously. address allowed market - with market to P.J. talked to commercial we few just existing we overlap that the and few alluded a the our good both use

some TKI need oncologists them value marketplace not drugs patients, but the educate that bring toward all that help these the also consistent new a help the So, that the very we we be standpoint HCC. really for been kind invest around could and to we've the IO being this on very build, into think side, market coming lot productive with the can help I That is idea and is then That that market again, we their therapies that us. the don't side, need move only the opportunity now to more to to address large medical on said, this with of that build, of able a for we be move from or hepatologists to them the second-line lines have sleeve. along underserved oncology

So, been be to ramp. that. in consistent about going this a is very slower We've talking

are many, and there's since We pieces by haven't predict, But by that's on hard to to fine. guidance us many moving hard and others. that given model both certainly HCC

were second-line stand at in I to letter weeks is the this terms literally, where getting indication think setting, COSMIC-XXX But, our interest, the commercially ready just of and the cabo/atezo these the market, patients go HCC the medical of have. to HCC in actually a reinvest few that today looking need ago. large as in for well. study, of sign clearly unmet The minutes approval again, we're first-line are and value a we within, we continuing certainly we of also, very committed

So, pushing work looking be of and to a lot in to here but the do we're excited certainly it mix forward forward. to

Operator

of Stifel. Your Stephen comes line with next from the Willey question

Your line is now open.

Stephen Willey

those regimen any to the progressed congratulations P.J. patients duration a of question Thanks see question quarter. the and of off those of a to patients ipi/nivo difference, for for Do off are terms taking who start. just you versus just for of Maybe TKI? on of have prior who progressing therapy, happen the noticeable in kind

P.J. Haley

to duration, in any on specific flow the I in what to dynamic duration always we've patient relatively seen is said We've think similar trials. regards that that patient seeing population. comment the early the With really to make we're

we - many the metrics - track CABOMETYX tracking progressors see data very we look of we're going something and that some in XX% and and, certainly certainly, nivo/ipi So, onto the carefully forward to to second-line encouraged future.

Stephen Willey

respect to that guess, just I then And with on of progressing, are who XX% patients ipi/nivo.

of in that sense that that are patients an XX% we had do still in XX% drug. think just updated trial of only regimens suggested still that kind or was is therapy. of yesterday point second-line this on that it, the on therapy? XXX went the that subsequently CheckMate second-line patients these the to study of patients if released might interesting front-line think novel know XX% Thanks. actually dynamic I some there's be receive curious specific think I it you But changing or trial see XXX kind you data that abstract environment I somehow systemic CheckMate is So, to in thought proportion of the of on another

Mike Morrissey

one. So, certainly progression of sites to the looks at be We what's that Is improve, asked relative we trial It's is data, same QX, having and the with NRx coming we question certainly cabo Mike. a comment too, after community, it pleased at think ipi/nivo. a etc.? to Steve, that I'll that and consequence you saw what that to clinical to And asked probably we're take there. see little in interesting. as on opposed it's there. it to trends of early happening patients QX end the relative

that the that's and XXX. that PFS of the internally with data launch consistent So, all timing saw we with

able data stay So, question. track that great and more data, on time be we So, of we'll just as patients, numbers. tuned. more Right? get goes and more to Certainly, Early days. more

Operator

Goldman with Choi Paul of line Sachs. proceed. Please the from comes question next Your

Paul Choi

Correct or for XX% contributed comment your but I think let's volume-price P.J., wrong, could in maybe if of on me say, I'm how by XXXX the my was approximately and about dynamic over, XXXX given volume if you the in growth wondering, landscape. XXXX. think, Mike either changing cabo you I math, RCC,

maybe sort forward reasonably volume think increases taken can short- annually, the you here? do you proxy to this of a how as price And think intermediate-term, So, price the versus growth? you've about about that going is that

Mike Morrissey

Thanks question. Fair for question. the

a around XXXX to in We've of grow of that not face QX grown data toward sure and the certainly like and that vectoring and drive or that question would competitive pressure. in sharing you. guidance we're quarters continued math least QX at comfortable I'm pretty You're with significant

in In in fact, obviously, the we based in QX, launched a upon were we XXXX. had We first-line the X% timeframe, X% that big that both TKI QX. only QX, quarter approval in growing in was when

the in I what's issue. certainly asking first-line looking you're what at impact consequence and second-line. has the it or first-line the guess the the we're happening what a is has question dynamic of key in So, on is Again, it and happens around impact the

So, will tell. time

data, times everything setting that and is continue, we're the will supporting outlined and that theory, we doing of some else second-line in on in regard. our as volume that think top growth provided today will I several drive pick-up hopefully, to grow we've that

we've of cover to be acknowledge one and pieces. but data, going that. a lot got, team, We It's great great into moving many momentum a XXXX that dynamic able again, complex to it's So, that.

Paul Choi

guess Chris any that you of the the you're share expense R&D line of CheckMate is with And either coming enrollment too from toward year-over-year the trial? I finish timeframes R&D that COSMIC-XXX components maybe future, for to XER for maybe also, the willing will and -XXX us on that, guidance one the the here primarily increase? completion there explain the on not component. are it the And, driving to distant can apart be in

Chris Senner

piece the So, I'll that. financial of take

So, say significant or that just XXXX. And stop when the I trial a doesn't XER contributor out - is the is to in when doesn't revealed. would expenses read data it data stop

were piece and big the when guess, point you versus started will incremental So, continue be any XXX incremental will and more and beyond from then that XXXX XXX so will compare I readout. 'XX just be because XXX perspective, they during of contributor a 'XX. later significant, And an on XXX

Gisela Schwab

on early dynamics accrual, the we and accrual this this point. at the we're In trials time, these at guidance of terms provide in don't

quarterly can indicated where expected regarding of back earlier the second think that Bristol-Myers to I I in be call we half what said the refer results XER XXXX. you their could study, in

Operator

Please question Jeff proceed. comes Stanley. from next of Your the Morgan with line Hung

Jeff Hung

inventory clarify. Thanks for of build correct? XQ, on from just taking top to inventory $X.X that the I build, questions. million wanted was The leftover the

Chris Senner

that's mean, to it, look the way at I yes.

said So, to weeks said during as in hand did QX, approximately did increase inventory story prepared on the weeks. QX and earlier, two I in I the half But to we here from And QX as an in story. go up real is XXX and see unit Andy my X.X in we see, total. demand a remarks,

in XX%. is As you demand XXXX, I P.J. this compare has demand almost X% growth when grew in And, Mike said, X% said earlier, mean, I XXXX, said, to QX, demand overall, in growth it QX.

clarify it information the but and really a comes from so where on demand demand story. We on story. there's provide it transparency the So, is the I'd growth focus inventory

Jeff Hung

balancing and And guys about about opportunities how acquiring terms But allocation, guys have then you profitability think I you assets? talked you guess looking in do BD capital and additional at. potential of been Thanks.

Mike Morrissey

of have to to the maneuver, There's think and that's assets we our to certainly certainly few But going and profitable forward. value add of both that years, be have strategic stay reasons depth years able an the generate certainly we've to and important last Yes, the regards a to and lot to we've and forward. tactical that Jeff, few we over over of part equation in value that spoken it's extensively. can financial Mike. room be profitable built last going

the point I the manage So, well. financially, to act we've as it's depth, a to certainly of think commercially, it's that experience, R&D one pretty as both balancing but got be view, well able from an clinically

Operator

Please with from of Bloomberg. Asthika proceed. Goonewardene the line Your next comes

Asthika Goonewardene

end. and taking at Thanks squeezing questions for me the in for my

real-world I the that a X.X hand, with more what's the on On year at PFS, wondering, cabo, then question. First you And the first-line for have data on a consistent now. was with does the label? data more. all approved label, couple for RCC is the the than I've real-world got

P.J. Haley

P.J. this Yes, is

we've think the mentioned in I a earlier, with duration consistent is bit seen what As the I trial.

getting it's we the data. patients the the certainly that and are encouraging benefit in gratifying saw So, that

Asthika Goonewardene

XER, RCC first-line some tell of maybe trial us seen we've could arms. far Bavencio, certain comparative so sites some And be Keytruda, these about better what I me, as you data combo as could you trials, representation you them if XER's recruitment etc. it, was with then the arm. with might one a know for which tell And of Excellent. nivo/ipi, well given wondering

Mike Morrissey

It's Mike. Fair question.

one it's I arguably comment somewhat challenging that not prospectively. for think probably cross-trial and it wise retrospectively It's is to to us or always comparisons, on. either make dangerous

don't would and guidance do that insight to we or really not there any So, want for give you.

Sorry.

Asthika Goonewardene

CKET, we patent right more this the you a patents potency it. is bit this in Last I dig terms cabo versus one? etc. might to up been MET is then we maybe if have RCC which for exactly XXX and this the VEGFR hits to color and contrast in And And see use we trying some HCC. XL, of please? targets, and beyond MET, It's XXX one also has what in have ask targeting ending the on to one. associated On get could VEGFX, we've as XLXXX, found the can little to think

Mike Morrissey

Mike. It's

least short-term. the stop can answer not patent in so it. an emphatic with I would I at So, that looking, hasn't yet The That's application published no. question

we pre-clinical the a of us some we'll of profile, again, momentum terms defer kind later context. additional In full story to that clinical put in to once have allow the would that date

our But, us As right there's the any in XX pretty action. a imagine, need with now no going excited we're competition again, back to you years. for that's enable competitive this DNA, looks space could about early almost at the back is I and data. in having discovery mean,

So, see able the have them to molecule. of Peter clinical tons correct. it's data world. And, we're and Gisela's out get into we're from just our hypotheses molecules information going very And potentially gratifying to some to have both lab knowledge a cabo cranking I better are next-generation, and put talked today, Peter as that if back about forward crew new to in and certainly, again, moving into we and

stay So, tuned.

Asthika Goonewardene

look guys, assets Thanks for the clinic year. to of and forward more coming out taking this question, the

Operator

Call proceed. comes the line Capital Management. of The Your Tim with from Please question next

Tim Call

again. on quarter great Congratulations a

have zero debt. You

the If the debt acquisition, what for right level be the optimal would company? find you

Mike Morrissey

in question. have that question access. to Yes, join how cash Glad terms time Mike. it's the Chris might that We in speculate for tactically a a used work, have either there. debt convert some might back done his Thanks Tim, to don't did XXXX so certainly to of we us We on, Gilead, past. we capital the going that could we to we want debt our today. have we the that you it's or help a had experience finance at expertise, his probably of we work. and debt back company put lot

that then have the it able questions, and of the would right the experience, deploy help to, the level do of capital right to we probably perspective, for prospectively. right depth a be But capital the way value company. So, maximize to from speculate think, analysis, right really the and be in I to unwise us ask on knowledge

Tim Call

$X.XX your shareholders option offset to by by returned year stock excessive your of be of balances rose this some to flow, cash free Because buying Should that cash dilution share. to around back per XX% shares? future

Mike Morrissey

question. good a provide Yes, some Chris, that's commentary. want I'll with you and that start to

Chris Senner

a in or of return more we're drive around growth less us, capital Sure. in and really and that is of to think of doing most assets the is important acquisition buyback really in to through shareholder mean, deploying the on We most life a acquisitions shareholder of company, the what licensing. as shareholder a that this point today. at BD driver important so value piece it's dividend. and I new and And finding deployment important the our around assets

share through I less growth say we never won't and Now, than do future licensing. driving actually a company of a won't buyback a never. that acquisitions that through I'll priority but is BD say or the in or dividend

Mike Morrissey

long-term reaffirm I thanks value. would the and going, we're long-term. as creation seems on to and a we're just be best where build we've And and value focused the where that sustainable But for to growth come over I from the Yes, question. company that. think, Look, way

Tim Call

your cumulative to very those Many of exceed reach or product any certain sales partner XXXX? escalation royalties you received collaboration percentage do in and of reach embedded reach any those your last clauses. Did reach up year those of thresholds nicely. and as revenue contracts future expect have attractive you product thresholds When you thresholds, goes or revenue

Chris Senner

did to yes, year, So, two last that. talk guess, about I we reach, thresholds

our and around we of cumulative And the was we $XXX So, XX%. $XXX million at rate royalty revenue. that through that was million the first at was the threshold cumulative hit minimum million $XXX got royalty of the next $XX piece, XX%. million first After of a now X%

On cumulative receive Ipsen beyond our second the million four one second recorded when the during know XX% XXXX and milestones to a not royalty from the future we next perspective. the at future them hit commercial be $XXX minimum So, annual is, speculate the to which over for rate just the that a I'm potential other Ipsen is earned basis, a quarter, milestone on of hit will And minimum we or basis, milestone royalty a that quarters, the going an XX%. on quarter. Ipsen, set during from but now, then did in

Operator

are you. And questions. at no Thank this time, further there

call.,. So, that, the will with turn I

Susan Hubbard

today. Great. and We us we for questions during you were follow-up all joining with to unable welcome certainly your today's Thanks, any Andrew, calls to thank call. get

Operator

thank gentlemen, disconnect. in may conference. you program today's does Everyone, day. wonderful for and a Ladies you participating conclude and This have all the

Exelixis (EXEL) 13 Feb 192018 Q4 Earnings call transcript